BCM3Beyond's analysis on BCM32026-08-18 — WuXi XDC’s GMP‑cleared BCM3 facility in Singapore expands its bioconjugate manufacturing capacity, positioning the CDMO to capture additional global contract workRecent news mentioning BCM32026-08-18 — WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional ExcellenceAppears alongsideWuXiXDCGMPBrowse the full archive →